Ann Oncol: Nivolumab (Nivolumab) second-line treatment does not improve the prognosis of small cell lung cancer: from CheckMate 331 clinical study

Small cell lung cancer (SCLC) is more sensitive to radiotherapy and chemotherapy, and the remission rate is higher in first-line treatment, but almost all experience recurrence.

Small cell lung cancer (SCLC) is more sensitive to radiotherapy and chemotherapy, and the remission rate is higher in first-line treatment, but almost all experience recurrence.

The study is a global open-label, randomized controlled phase III clinical study (ClinicalTrials.

The study is a global open-label, randomized controlled phase III clinical study (ClinicalTrials.

A total of 569 patients were included in the study, of which 284 patients were randomly assigned to the nivolumab group for treatment, and 285 patients were randomly assigned to the chemotherapy group for treatment.

OS, PFS and DOR analysis of the two groups

The ORRs of the two groups were 13.

The ORRs of the two groups were 13.

Two groups of treatment for ORR and DOR

According to the group analysis of PDL1 expression level, when PDL1 CPS ≥ 1%, the median OS of nivolumab and chemotherapy groups were 7.

According to the group analysis of PDL1 expression level, when PDL1 CPS ≥ 1%, the median OS of nivolumab and chemotherapy groups were 7.

 Hierarchical analysis of the two groups of OS and PFS according to PDL1

The incidences of treatment-related adverse events (TRAEs) of any grade in the two groups were 55.

The incidences of treatment-related adverse events (TRAEs) of any grade in the two groups were 55.

Treatment-related adverse events

To sum up: Nivolumab (Nivolumab) compared with second-line chemotherapy cannot improve the prognosis of recurrent small cell lung cancer.

To sum up: Nivolumab (Nivolumab) compared with second-line chemotherapy cannot improve the prognosis of recurrent small cell lung cancer.
No new adverse events were found.
Subgroup analysis found that some selective patients may benefit from nivolumab OS, such as patients with lactate dehydrogenase (LDH) less than or equal to the upper limit of normal (ULN) at baseline and patients without liver metastases.
Nivolumab (Nivolumab) compared with second-line chemotherapy does not improve the prognosis of recurrent small cell lung cancer.
No new adverse events were found.
Subgroup analysis found that some selective patients may benefit from nivolumab OS, such as patients with lactate dehydrogenase (LDH) less than or equal to the upper limit of normal (ULN) at baseline and patients without liver metastases.
Nivolumab (Nivolumab) compared with second-line chemotherapy does not improve the prognosis of recurrent small cell lung cancer.
No new adverse events were found.
Subgroup analysis found that some selective patients may benefit from nivolumab OS, such as patients with lactate dehydrogenase (LDH) less than or equal to the upper limit of normal (ULN) at baseline and patients without liver metastases.

Original source:

Original source:

DR Spigel, D Vicente, TE Ciuleanu, et al.
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331.
Ann Oncol.
2021 May;32(5):631-641.
doi: 10.
1016/j.
annonc.
2021.
01.
071.
Epub 2021 Feb 1.

D R Spigel, D Vicente, T E Ciuleanu, et al.
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331.
Ann Oncol.
2021 May;32(5):631-641.
  doi: 10.
1016/j.
annonc.
2021.
01.
071.
Epub 2021 Feb 1.